GeoVax Announces Issuance of Malaria Vaccine Patent
03 Janvier 2024 - 3:00PM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced
that the U.S. Patent and Trademark Office has issued Patent No.
11,857,611 to GeoVax, pursuant to the Company’s patent application
No. 17/726,254 titled “Compositions and Methods for Generating an
Immune Response to Treat or Prevent Malaria.”
The claims granted by the patent generally cover
compositions comprising GeoVax’s modified vaccinia Ankara (MVA)
vector expressing Plasmodium antigens and methods of inducing an
immune response to malaria utilizing the compositions. The
compositions and methods covered in the claims are useful both
prophylactically and therapeutically and may be used to prevent
and/or treat malaria.
David Dodd, GeoVax President and CEO, commented,
“During 2023, there were the first cases of locally transmitted
malaria reported in the United States in 20 years, with cases
reported in Florida, Maryland and Texas. Worldwide, there are over
600,000 deaths annually attributed to malaria. This patent
represents a potentially significant advance against a most
critical deadly threat worldwide. While our focus and priority is
to support our clinical-stage programs, we also remain strongly
committed to improving public health worldwide and developing
vaccines against global public health threats, such as malaria, as
a part of our long-term vision for the company.”
According to data from the World Health
Organization, globally, malaria causes 227 million infections and
619,000 deaths annually. Despite decades of vaccine research,
vaccine candidates have failed to induce substantial protection.
Most of these vaccines are based on individual proteins that induce
immune responses targeting only one stage of the malaria parasite’s
life cycle. GeoVax’s MVA-VLP malaria vaccine candidates incorporate
antigens derived from multiple stages of the parasite’s life cycle
and are designed to induce an immune response with durable
functional antibodies and CD4+ and CD8+ T cell responses, all
hallmarks of an ideal vaccine-induced immune response.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in three
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary
vaccine for immunocompromised patients such as those suffering from
hematologic cancers and other patient populations for whom the
current authorized COVID-19 vaccines are insufficient, and as a
booster vaccine in patients with chronic lymphocytic leukemia
(CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial
evaluating the vaccine as a more robust, durable COVID-19 booster
among healthy patients who previously received the mRNA vaccines.
GeoVax has a leadership team who have driven significant value
creation across multiple life science companies over the past
several decades. For more information, visit our
website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our periodic reports on Form 10-Q and Form 10-K that
we have filed and will file with the SEC. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law.
Company
Contact: |
|
Investor
Relations Contact: |
|
Media
Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
GeoVax Labs (NASDAQ:GOVX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
GeoVax Labs (NASDAQ:GOVX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024